Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Abeona Therapeutics Inc has a consensus price target of $15.86 based on the ratings of 7 analysts. The high is $21 issued by Stifel on May 30, 2024. The low is $6 issued by SVB Leerink on November 14, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co. on March 24, 2025, March 5, 2025, and February 19, 2025, respectively. With an average price target of $15.33 between HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co., there's an implied 208.52% upside for Abeona Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/24/2025 | Buy Now | 201.81% | HC Wainwright & Co. | Mitchell Kapoor45% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
03/05/2025 | Buy Now | 221.93% | Oppenheimer | Francois Brisebois44% | → $16 | Initiates | → Outperform | Get Alert |
02/19/2025 | Buy Now | 201.81% | HC Wainwright & Co. | Mitchell Kapoor45% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
11/25/2024 | Buy Now | 201.81% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
10/31/2024 | Buy Now | 201.81% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
10/29/2024 | Buy Now | 262.17% | Cantor Fitzgerald | Kristen Kluska71% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
09/20/2024 | Buy Now | 262.17% | Cantor Fitzgerald | Kristen Kluska71% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
08/14/2024 | Buy Now | 201.81% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
07/12/2024 | Buy Now | 201.81% | HC Wainwright & Co. | Raghuram Selvaraju43% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
07/03/2024 | Buy Now | 201.81% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $15 | Initiates | → Buy | Get Alert |
05/30/2024 | Buy Now | 322.54% | Stifel | Dae Gon Ha49% | → $21 | Initiates | → Buy | Get Alert |
05/16/2024 | Buy Now | 322.54% | Cantor Fitzgerald | Kristen Kluska71% | $28 → $21 | Maintains | Overweight | Get Alert |
04/23/2024 | Buy Now | 624.35% | Cantor Fitzgerald | Kristen Kluska71% | $36 → $36 | Reiterates | Overweight → Overweight | Get Alert |
08/24/2023 | Buy Now | 664.59% | Cantor Fitzgerald | Kristen Kluska71% | → $38 | Reiterates | Overweight → Overweight | Get Alert |
07/13/2023 | Buy Now | 664.59% | Cantor Fitzgerald | Kristen Kluska71% | → $38 | Reiterates | Overweight → Overweight | Get Alert |
05/24/2023 | Buy Now | 302.41% | Alliance Global Partners | James Molloy30% | → $20 | Reiterates | → Buy | Get Alert |
11/14/2022 | Buy Now | 20.72% | SVB Leerink | Mani Foroohar46% | $5 → $6 | Maintains | Market Perform | Get Alert |
11/08/2022 | Buy Now | 704.83% | Cantor Fitzgerald | Kristen Kluska71% | $22 → $40 | Maintains | Overweight | Get Alert |
08/11/2022 | Buy Now | 0.6% | SVB Leerink | Mani Foroohar46% | $1 → $5 | Maintains | Market Perform | Get Alert |
The latest price target for Abeona Therapeutics (NASDAQ:ABEO) was reported by HC Wainwright & Co. on March 24, 2025. The analyst firm set a price target for $15.00 expecting ABEO to rise to within 12 months (a possible 201.81% upside). 13 analyst firms have reported ratings in the last year.
The latest analyst rating for Abeona Therapeutics (NASDAQ:ABEO) was provided by HC Wainwright & Co., and Abeona Therapeutics reiterated their buy rating.
There is no last upgrade for Abeona Therapeutics
There is no last downgrade for Abeona Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abeona Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abeona Therapeutics was filed on March 24, 2025 so you should expect the next rating to be made available sometime around March 24, 2026.
While ratings are subjective and will change, the latest Abeona Therapeutics (ABEO) rating was a reiterated with a price target of $15.00 to $15.00. The current price Abeona Therapeutics (ABEO) is trading at is $4.97, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.